内分泌学
胰岛素抵抗
内科学
产热
NEFA公司
脂质代谢
脂类学
脂肪组织
化学
安普克
肥胖
脂肪细胞
胰岛素
生物化学
生物
医学
酶
蛋白激酶A
作者
Minchuan Zhou,Jingqing Huang,Jingwen Zhou,Cuiting Zhi,Yan Bai,Qishi Che,Hua Cao,Jiao Guo,Zhengquan Su
出处
期刊:Molecules
[MDPI AG]
日期:2023-07-23
卷期号:28 (14): 5595-5595
被引量:7
标识
DOI:10.3390/molecules28145595
摘要
Chitooligosaccharide (COS) is a natural product from the ocean, and while many studies have reported its important role in metabolic diseases, no study has systematically elaborated the anti-obesity effect and mechanism of COS. Herein, COSM (MW ≤ 3000 Da) was administered to diet-induced obese mice by oral gavage once daily for eight weeks. The results show that COSM administration reduced body weight; slowed weight gain; reduced serum Glu, insulin, NEFA, TC, TG, and LDL-C levels; increased serum HSL and HDL-C levels; improved inflammation; and reduced lipid droplet size in adipose tissue. Further lipidomic analysis of adipose tissue revealed that 31 lipid species are considered to be underlying lipid biomarkers in COS therapy. These lipids are mainly enriched in pathways involving insulin resistance, thermogenesis, cholesterol metabolism, glyceride metabolism and cyclic adenosine monophosphate (cAMP), which sheds light on the weight loss mechanism of COS. The Western blot assay demonstrated that COSM intervention can improve insulin resistance, inhibit de novo synthesis, and promote thermogenesis and β-oxidation in mitochondria by the AMPK pathway, thereby alleviating high-fat diet-induced obesity. In short, our study can provide a more comprehensive direction for the application of COS in obesity based on molecular markers.
科研通智能强力驱动
Strongly Powered by AbleSci AI